Pipeline
TLY012
TLY012 is a trimeric recombinant human TRAIL designed to selectively induce apoptosis in activated myofibroblasts, the key driver of multiple fibrotic diseases, through DR5-mediated apoptotic pathways. This targeted approach addresses the underlying cause of fibrosis, offering a novel therapeutic strategy for treating fibrotic conditions.
Do you have any questions for Theraly Fibrosis?
For questions regarding our current Development stage, Please Contact [email protected]